東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Formulating poorly water soluble drugs

Williams, Robert O.

FindBook

Google Book

Amazon

博客來

Formulating poorly water soluble drugs

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Formulating poorly water soluble drugs/ edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.
其他作者:	Williams, Robert O.
出版者:	Cham :Springer International Publishing : : 2022.,
面頁冊數:	xii, 693 p. :ill. (some col.), digital ;24 cm.
內容註:	Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.
Contained By:	Springer Nature eBook
標題:	Drugs - Design. -
電子資源:	https://doi.org/10.1007/978-3-030-88719-3
ISBN:	9783030887193

Formulating poorly water soluble drugs
Formulating poorly water soluble drugs[electronic resource] /edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. - Third edition. - Cham :Springer International Publishing :2022. - xii, 693 p. :ill. (some col.), digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v. 502210-738X ;. - AAPS advances in the pharmaceutical sciences series ;v. 50..

Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.

The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.

ISBN: 9783030887193

Standard No.: 10.1007/978-3-030-88719-3doiSubjects--Topical Terms:

664528
Drugs
--Design.

LC Class. No.: RM301.25

Dewey Class. No.: 615.19

Formulating poorly water soluble drugs
LDR:03539nmm a2200349 a 4500 001 2299700
003 DE-He213
005 20220519132730.0
006 m d
007 cr nn 008maaau
008 230324s2022 sz s 0 eng d
020 $a 9783030887193 $q (electronic bk.)
020 $a 9783030887186 $q (paper)
024 7 $a 10.1007/978-3-030-88719-3 $2 doi
035 $a 978-3-030-88719-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a PSB $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a PNB $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .F726 2022
245 0 0 $a Formulating poorly water soluble drugs $h [electronic resource] / $c edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.
250 $a Third edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a xii, 693 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-738X ; $v v. 50
505 0 $a Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.
520 $a The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.
650 0 $a Drugs $x Design. $3 664528
650 0 $a Drugs $x Solubility. $3 2017970
650 1 4 $a Pharmaceutics. $3 3538434
650 2 4 $a Pharmacology. $3 634543
650 2 4 $a Medical Biochemistry. $3 892387
700 1 $a Williams, Robert O. $3 1566953
700 1 $a Davis, Daniel A. $3 1912944
700 1 $a Miller, Dave A. $3 1566955
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v v. 50. $3 3597438
856 4 0 $u https://doi.org/10.1007/978-3-030-88719-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)